JOURNAL OF CLINICAL PATHOLOGY临床病理学杂志
JOURNAL OF CLINICAL PATHOLOGY(英文缩写 J CLIN PATHOL),ISSN 0021-9746,eISSN 1472-4146,中文译名:临床病理学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.467 | Q2 |
| 2022 | 3.400 | Q2 |
| 2023 | 2.500 | Q2 |
| 2024 | 2.000 | Q2 |
| 2025 | 2.600 | Q2 |
JOURNAL OF CLINICAL PATHOLOGY 最新收录文献
-
1. Adapt or Become Irrelevant: the Pathologist as the new Diagnostic Architect.
PMID:日期:2026-09-18Pathology is undergoing a paradigm shift as diagnostics become increasingly multimodal and computational. Yet legacy structures, incentives and workflows have not yet evolved. This misalignment created systemic vulnerabilities that threaten diagnostic precision and the profession's future. Here, we establish a framework for the cognitive integration of rapidly evolving diagnostic innovations in pathology. To characterise critical inflection points and opportunities for conceptual transformation we mapped seven diagnostic scenarios: programmed death ligand 1 testing, next-generation sequencing reimbursement constraints, artificial intelligence-based triaging, integrated diagnostics, germline (pharmacogenomics) testing, trial design and emerging assurance frameworks outside traditional pathology. Our synthesis draws from peer-reviewed literature, policy analysis, institutional data, and qualitative insights to highlight where pathologists can elevate their role as integrator of clinical, morphological and molecular knowledge. Across the seven scenarios, common patterns emerged: unintentional consequences of well-intended initiatives, commoditisation, unsustainable economic models, underleveraged efficiency gains, misaligned infrastructure, missed clinical opportunity, regulatory rigidity and erosion of diagnostic accountability. These patterns signal not only operational gaps but a cognitive crisis. A failure by pathologists to position themselves as more than an interpretative service. Pathologists must assume the role of diagnostic architects, synthesising multimodal data into structured, clinically actionable insights and engaging more directly with physicians, those organising clinical trials and patients as partners in precision medicine. The emerging competencies of diagnostic synthesis, systems thinking, digital fluency, and strategic presence in value-based care offer a mindset guide for both personal growth and anchoring the discipline's next transformational step to improve patient care.
-
2. Targeted transcriptome profiling of oral cavity squamous cell carcinoma and histologic grade-associated gene expression patterns.
PMID:日期:2026-09-18To characterise gene expression differences between oral cavity squamous cell carcinoma (OSCC) and non-neoplastic oral mucosa using targeted transcriptome profiling and to evaluate gene expression patterns associated with tumour differentiation. Formalin-fixed, paraffin-embedded tissue from 16 resected OSCCs (3 well differentiated, 9 moderately differentiated and 4 poorly differentiated) and 7 non-neoplastic oral mucosa samples was analysed. RNA was isolated from microdissected tissue and profiled using a targeted next-generation sequencing assay. Differential gene expression and pathway enrichment analyses were performed, including comparisons across histologic grades. OSCC demonstrated broad transcriptomic differences compared with non-neoplastic oral mucosa, with enrichment of pathways related to extracellular matrix remodelling, cell adhesion, immune regulation, oncogenic signalling and cellular metabolism. Grade-stratified analyses identified additional differences involving epithelial differentiation, immune response, lipid metabolism and oxidative phosphorylation pathways. OSCC exhibits broad transcriptomic dysregulation involving extracellular matrix remodelling, cell adhesion, immune signalling, oncogenic signalling and cellular metabolism. Grade-stratified findings demonstrate molecular differences associated with tumour differentiation but require validation in larger independent cohorts. These findings may inform future studies of biomarkers and biologically relevant pathways in OSCC.
-
3. Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma.
PMID:日期:2026-09-18Specific to normal gastric epithelium, Claudin 18.2 (CLDN18.2) is a tight junction protein. CLDN18.2 immunohistochemistry is a companion diagnostic used to identify oesophageal and gastric adenocarcinoma patients eligible for targeted therapy with zolbetuximab. It has demonstrated survival benefits in advanced upper gastrointestinal (UGI) cancers, with many studies now exploring its potential use beyond the UGI tract. This study aimed to examine CLDN18.2 expression in a peritoneal malignancy patient cohort. CLDN18.2 immunohistochemistry was performed on archived tissue from patients who underwent cytoreductive surgery at a national centre for peritoneal malignancy. CLDN18.2 immunoprofiles were compared in two key tumour cohorts: peritoneal metastases from colorectal adenocarcinoma and appendiceal mucinous neoplasms. Positivity was defined as moderate-to-strong membranous staining in 75% of tumour cells. In addition, any CLDN18.2 positivity in tumour cells (>0% of cells showing moderate-to-strong membranous staining) was recorded in all cases. 64 cases were examined; primary tumour sites of origin were colorectal (n=34, 53%) and appendiceal (n=30, 47%). CLDN18.2 positivity in the overall appendiceal group was 17% compared with 3% in colorectal adenocarcinomas (p=0.090). In the appendiceal group, CLDN18.2 positivity was only demonstrated in high-grade appendiceal mucinous carcinomas (22%, 5 of 23). CLDN18.2 positive staining (>0% of tumour cells) was significantly increased in the appendiceal group compared with colorectal adenocarcinoma (53% vs 3%, respectively) (p<0.0001). These results demonstrate CLDN18.2 expression in a subset of appendiceal peritoneal metastases. This is one of the first focused studies showing CLDN18.2 expression in this tumour group, perhaps highlighting a future role for targeted therapies in those with limited curative oncological options.
-
4. Serum versus lithium-heparin plasma for lipid testing: matrix-related bias and calculated LDL-C classification.
PMID:日期:2026-09-18To assess whether serum and lithium-heparin plasma can be used interchangeably for routine lipid testing and whether matrix-related bias affects calculated low-density lipoprotein (LDL)-cholesterol (LDL-C) classification near clinical decision thresholds. This prospective paired-sample method-comparison study included 104 fasting adult ambulatory patients referred for routine lipid testing. Serum and lithium-heparin plasma were collected during the same venipuncture and analysed on a Cobas 6000 c501 analyser. LDL-C was calculated using the Friedewald equation when triglycerides (TGs) were <4.5 mmol/L (n=103). Agreement was assessed using paired testing, Passing-Bablok regression, Bland-Altman analysis, intraclass correlation coefficients (ICCs), Cohen kappa and McNemar testing at selected decision thresholds. Interchangeability was interpreted using analytical bias, measurement uncertainty, limits of agreement and threshold discordance. Lithium-heparin plasma yielded lower total cholesterol and calculated LDL-C than serum, with mean biases (plasma - serum) of -0.15 mmol/L (-3.06%) and -0.14 mmol/L (-4.77%), respectively. TGs and HDL-cholesterol did not differ significantly. Serum-plasma correlations and ICCs were high. LDL-C classification was discordant in 3/103, 2/103 and 7/103 paired samples at thresholds of 1.4, 1.8 and 2.6 mmol/L, respectively; all discordances classified plasma below and serum above the threshold. Under these local analytical and pre-analytical conditions, the mean bias was modest but directional and sufficient to alter calculated LDL-C classification in a minority of samples near decision thresholds. Laboratories using lithium-heparin plasma for lipid testing should verify matrix agreement locally, document the specimen matrix and avoid alternating serum and plasma during longitudinal monitoring unless equivalence has been demonstrated.
-
5. Beyond root cause analysis: a practical systems engineering approach to incident investigation in histopathology.
PMID:日期:2026-09-18Patient safety and diagnostic quality are central to modern histopathology practice. Current incident investigation approaches often rely on root cause analysis; however, its routine use as a universal method is insufficient to address the highly variable, cognitive, sociotechnical and multifactorial nature of histopathology errors. In practice, incidents range from simple technical failures to complex system-level events requiring distinct investigative strategies. A key limitation of current practice is the lack of proportionality, where similar methods are applied irrespective of case complexity. In addition, corrective actions frequently target the immediate error without adequately considering the broader system context, potentially increasing workload, introducing new risks or degrading long-term service performance and operational sustainability. In this narrative review, we propose a practical five-stage systems framework for incident management in histopathology. This framework integrates proportional incident classification, structured systems investigation, prospective evaluation of corrective actions to minimise unintended consequences, implementation of system-level improvements and continuous performance monitoring. By selectively applying established human factors and quality improvement methodologies according to incident complexity, the framework shifts incident management from retrospective error investigation towards proactive system optimisation and continuous organisational learning. Ultimately, it provides a practical, scalable approach that improves diagnostic reliability, reduces recurrence, enhances efficiency and ensures that corrective actions are effective, sustainable and aligned with real-world laboratory practice.
-
6. Developing a national proficiency testing programme for biospecimens: the Thailand Biobank Consortium experience.
PMID:日期:2026-09-18To address the absence of nationally accessible proficiency testing (PT) for biospecimens in Thailand, we developed and evaluated a pilot PT programme consisting of four schemes covering DNA extraction, quantification, purity and integrity assessment. The pilot PT programme comprised two schemes: DNA extraction from whole blood (P-DNABLD) and frozen tissue (P-DNAFRT) and two schemes: DNA quantification and purity (T-DNAQ) and DNA integrity (T-DNAI). All schemes were conducted in accordance with ISO/IEC 17043:2023 and ISO 13528:2022. PT items were assessed for homogeneity and stability, and participant performance was evaluated based on consensus values using - or '-scores. All PT items satisfied the ISO 13528:2022 requirements for homogeneity and stability after accounting for instability-related uncertainty in T-DNAQ. 30 laboratories participated nationwide in at least one scheme (P-DNABLD, n=28; P-DNAFRT, n=17; T-DNAQ, n=29; T-DNAI, n=13). All PT items were received within 3 days of dispatch, with ≥90% arriving within the acceptable temperature range. DNA extraction yield-related measurands demonstrated substantial interlaboratory variability (CV 78.2‒95.3%), whereas purity and integrity measurands were more consistent (CV 1.3‒11.2%). In T-DNAQ, A/A showed the greatest interlaboratory variability (CV 8.2‒16.4%); within-platform variability was low in T-DNAI. Across all schemes, ≥75% of participants achieved at least Satisfactory performance (|z or z'| ≤ 2.0). Direct costs were approximately 12% of those of comparable international PT schemes. This pilot demonstrates the feasibility and accessibility of a nationally coordinated PT programme for biospecimens and supports the establishment of a sustainable PT framework to harmonise biospecimen quality practices.
-
7. Artificial Intelligence in Digital Pathology for Prostate Cancer Detection: FDA Clearance and Real-World Implementation.
PMID:日期:2026-09-18Artificial intelligence (AI) has emerged as a promising adjunct in surgical pathology, particularly in the diagnosis of prostate cancer, where variability in interpretation or missed cancer foci can significantly affect patient management. This review provides a concise, practice-oriented overview of the two Food and Drug Administration (FDA)-cleared AI tools for prostate biopsy interpretation: Paige Prostate Detect and Ibex Prostate Detect (formerly Galen Second Read). We examine their regulatory indications, diagnostic performance and integration requirements within digital pathology workflows. Emphasis is placed on real-world implementation considerations, including variation in technical inputs and the level at which data are analysed. We highlight less obvious risks, such as domain shift and the potential for inequitable performance in under-represented patient populations. Trade-offs between sensitivity and specificity, particularly in the context of AI-assisted pathologist assessments, are discussed using data from clinical validation studies. We also consider the variable impact of AI tools depending on the user's expertise, noting enhanced diagnostic consistency for general pathologists. By highlighting both the opportunities and limitations of integrating AI into routine practice, we aim to provide pathologists with a pragmatic understanding of how these systems may influence diagnostic workflows and to emphasise that FDA clearance must be complemented by local validation as well as ongoing performance monitoring to ensure safe and equitable deployment.
-
8. MILGDF: a multi-task, instance-level supervised model for oral squamous cell carcinoma integrating local-global attention and dynamic decision fusion.
PMID:日期:2026-09-18This research was designed to establish an innovative diagnostic strategy employing whole-slide imaging (WSI) technology to address the diagnostic difficulties arising from the intricate histological architecture and morphological diversity observed in oral squamous cell carcinoma (OSCC). The developed methodology enables precise early identification and histomorphology-driven prognostic stratification of malignant lesions, thereby improving clinical management and patient prognosis. We propose a multi-task learning framework that combines local-global attention mechanisms with adaptive decision fusion (MILGDF). This model utilises instance-level category-specific attention to enhance feature extraction efficacy while overcoming the limitations inherent in traditional bag-level attention methods. An adaptive weighting system was incorporated to dynamically adjust the contribution of local and global features, ensuring optimal performance in dual tasks of OSCC diagnosis and prognostic stratification. Rigorous validation on the HIDOC and TCGA-OSCC datasets revealed the predictive performance of our model. The MILGDF framework attained an area under the curve of 0.952 (accuracy: 0.909) on HIDOC and 0.745 (accuracy: 0.725) on TCGA-OSCC. Statistical comparison using DeLong's test and paired t-tests demonstrated significantly superior performance (p<0.05) over existing comparative models in both diagnostic classification and prognostic stratification. Our findings demonstrate that the MILGDF model represents an improvement in whole-slide image-based OSCC analysis, delivering enhanced diagnostic accuracy and prognostic reliability relative to current approaches. The framework's consistent performance highlights its computational benchmark value and preliminary translational potential for early OSCC detection and auxiliary treatment planning, serving as a valuable asset for prognostic evaluation and therapeutic strategy formulation.